Research on treatments for small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) is ongoing, with several companies and organizations presenting preliminary data from phase 1 trials. Companies such as Legend Biotech and Abdera Therapeutics have unveiled results for various therapies, including radiopharmaceuticals and CAR-T cell treatments. The emergence of new data and research goals from multiple entities suggests a potential shift in the treatment landscape for these conditions.